Xerostomia Pipeline Summary

DelveInsight’s, “Xerostomia Pipeline Insight, 2026” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Xerostomia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Xerostomia Disease Understanding

Xerostomia Overview

Xerostomia, commonly known as dry mouth, is the subjective sensation of oral dryness that is typically caused by reduced saliva production, although some individuals may experience symptoms despite having normal salivary flow. Decreased saliva secretion can lead to oral discomfort, burning sensations, difficulty swallowing, impaired taste, and an increased risk of oral health complications. The condition most commonly arises as a side effect of medications, following head and neck radiation therapy, or in association with autoimmune disorders such as Sjögren syndrome. Management primarily focuses on relieving symptoms through patient education, including regular water intake and avoidance of tobacco, along with supportive measures such as artificial saliva substitutes. When these approaches are insufficient, pharmacological agents such as pilocarpine may be prescribed to stimulate saliva production.

 

Xerostomia is a multifactorial condition that most commonly occurs as a side effect of medications, following head and neck radiation therapy, or in association with Sjögren syndrome. Medication-induced xerostomia is particularly prevalent among older adults due to polypharmacy and comorbidities, with commonly implicated drug classes including anticholinergics, antidepressants, antipsychotics, diuretics, antihypertensives, sedatives, anxiolytics, muscle relaxants, analgesics, and antihistamines. Radiation therapy involving the major salivary glands can significantly impair salivary function, with saliva production declining rapidly during treatment and often failing to recover fully, especially at higher radiation doses. Sjögren syndrome, an autoimmune disorder characterized by chronic lymphocytic infiltration and damage to the salivary glands, is another major cause of xerostomia and predominantly affects women over 40 years of age. Additional causes include autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, thyroid disorders, and primary biliary cholangitis, as well as dehydration, mouth breathing, poorly controlled diabetes, head and neck nerve injury, end-stage renal disease, graft-versus-host disease, and HIV/AIDS.

Xerostomia develops when normal salivary gland function is disrupted by impaired neural stimulation or direct glandular damage. Under normal conditions, salivary secretion is triggered by acetylcholine acting on muscarinic (primarily M3) receptors in response to stimuli such as smell, taste, or chewing. Medication-induced xerostomia occurs when drugs suppress acetylcholine release or block muscarinic and adrenergic receptors involved in salivary secretion. Radiation-induced xerostomia results from damage to the salivary glands during head and neck radiotherapy, particularly the radiosensitive serous acinar cells of the parotid glands, leading to reduced saliva production, thicker saliva, chronic inflammation, acinar atrophy, and fibrosis. In Sjögren syndrome, autoimmune-mediated lymphocytic infiltration, primarily involving CD4+ T cells and B cells, causes progressive destruction and fibrosis of the salivary glands, with anti-SSA (Ro) and anti-SSB (La) antibodies serving as key diagnostic markers. The resulting impairment in glandular function and neural signaling leads to diminished saliva secretion and the characteristic symptoms of oral dryness.

 

Xerostomia is primarily diagnosed through a detailed patient history and physical examination, with subjective complaints of oral dryness often sufficient to initiate treatment, even in the absence of measurable reductions in salivary flow. Because numerous medications are associated with xerostomia, a thorough review of the patient's medication history is essential. When objective assessment is required, diagnostic techniques include sialometry to measure salivary flow rates, sialography, including three-dimensional magnetic resonance sialography, to evaluate salivary gland structure and function, particularly following radiation therapy, and salivary gland biopsy when systemic diseases or salivary gland pathology are suspected. In patients with suspected secondary Sjögren syndrome, additional clinical features of autoimmune disease, along with laboratory abnormalities such as elevated erythrocyte sedimentation rate (ESR), anemia, leukopenia, rheumatoid factor, or disease-specific autoantibodies, and characteristic lymphocytic infiltration on minor salivary gland biopsy, can help confirm the diagnosis.

The primary objective of xerostomia management is to relieve symptoms while addressing the underlying cause whenever possible, such as modifying xerogenic medications or treating conditions that contribute to oral dryness. Initial management emphasizes patient education and lifestyle modifications, including frequent water intake, chewing sugar-free gum or candy, avoiding caffeine, alcohol, tobacco, and dry foods, maintaining adequate hydration, and practicing good oral hygiene. Supportive measures such as artificial saliva substitutes (sprays, gels, and lozenges) can provide temporary relief, although their effectiveness and duration of action are limited. When conservative measures are insufficient, pharmacological treatment with FDA-approved salivary stimulants such as pilocarpine and cevimeline may be used in patients with residual salivary gland function. Other therapeutic options, including topical physostigmine, malic acid for drug-induced xerostomia, and anethole trithionate, have shown potential benefits in selected patients. Additional approaches, such as electrical stimulation devices and amifostine for patients undergoing head and neck radiotherapy, may also help improve salivary function in specific clinical settings.

 

"Xerostomia Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Xerostomia pipeline landscape is provided which includes the disease overview and Xerostomia treatment guidelines. The assessment part of the report embraces, in depth Xerostomia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Xerostomia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Xerostomia Pipeline Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Xerostomia R&D. The therapies under development are focused on novel approaches to treat/improve Xerostomia.

Xerostomia Emerging Drugs Chapters

This segment of the Xerostomia report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Xerostomia Emerging Drugs

AAV2-hAQP1: Meira GTx

AAV2-hAQP1 (AAV-hAQP1) is an investigational adeno-associated virus serotype 2 (AAV2)-based gene therapy being developed by MeiraGTx for the treatment of radiation-induced xerostomia (RIX) in patients who experience persistent dry mouth following radiotherapy for head and neck cancer. The therapy delivers the human aquaporin-1 (hAQP1) gene directly to damaged salivary glands, enabling the expression of aquaporin-1 water channels that restore water transport into the salivary ducts and improve saliva production. Administered as a one-time, minimally invasive intraductal infusion through the parotid duct, AAV2-hAQP1 is designed to provide durable restoration of salivary gland function rather than temporary symptomatic relief. The program is currently in Phase 3/registrational development (supported by the potentially pivotal AQUAx2 study), and has received FDA Breakthrough Therapy Designation, Regenerative Medicine Advanced Therapy (RMAT) Designation, and Orphan Drug Designation for the treatment of Grade 2/3 radiation-induced xerostomia. According to company’s pipeline the drug is in phase III stage of it’s development for the treatment of radiation-induced xerostomia.

Further product details are provided in the report...

Xerostomia Therapeutic Assessment

This segment of the report provides insights about the different Xerostomia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Xerostomia

There are approx. 3+ key companies which are developing the therapies for Xerostomia. The companies which have their Xerostomia drug candidates in the most advanced stage, i.e. Phase III include, Meira GTx.

Xerostomia Drugs Phases

DelveInsight’s report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Xerostomia Drugs Route of Administration

Xerostomia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Xerostomia Drugs Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Xerostomia Pipeline Product Type

• Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Xerostomia Pipeline Development Activities

The Xerostomia Pipeline report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Xerostomia therapeutic drugs key players involved in developing key drugs.

Xerostomia Clinical Trials and Development Activities

The Xerostomia clinical trials analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Xerostomia drugs.

Xerostomia Pipeline Report Insights

• Xerostomia Pipeline Analysis
• Xerostomia Therapeutic Assessment
• Xerostomia Unmet Needs
• Impact of Xerostomia Drugs

Xerostomia Pipeline Report Assessment

• Xerostomia Pipeline Product Profiles
• Xerostomia Therapeutic Assessment
• Xerostomia Pipeline Assessment
• Inactive Xerostomia drugs assessment
• Xerostomia Unmet Needs

Key Questions Answered in the Xerostomia Pipeline Report:

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Xerostomia drugs?
• How many Xerostomia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Xerostomia?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Xerostomia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Xerostomia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Xerostomia Companies

• MeiraGTx, LLC
• RiboX Therapeutics Ltd

Key Xerostomia Pipeline Products

• AAV2-hAQP1
• RXRG001